The Distinct Properties of Polysaccharide Nanoparticles Tune Immune Responses against mRNA Antigen via Stimulator of Interferon Genes-Mediated Autophagy and Inflammasome
Source abstract
Abstract
mRNA antigens require powerful nanocarriers for efficient delivery, as well as immunomodulators for controlling their excessive immunogenicity. While lipid nanoparticles (LNPs) used in mRNA vaccines exhibited systemic toxicity, there is an urgent need for developing potential nanoparticles with strong immunoenhancing effects for mRNA antigens. Although natural polysaccharides as adjuvants assisted various types of antigens in triggering potent immune responses, they have been rarely investigated in mRNA vaccines. Here, we constructed four polysaccharide nanoparticles with different molecular weights (MWs) to deliver and protect mRNA antigens, and boosted antigen cross-presentation, DC maturation, CD4 + /CD8 + T cell responses and humoral immune responses. Importantly, the immunoenhancing capacities of polysaccharide nanoparticles were highly dependent on their MW properties. CS NPs with high MW initiated stimulator of interferon genes (STING)-mediated autophagy and NOD-like receptor thermal protein domain associated protein 3 (NLRP3) inflammasome signaling, consequently possessing superior mRNA antigen-specific immune responses in vitro and in vivo . In contrast, CS NPs with low MWs induced NLRP3 signaling without STING or autophagy activation, which failed to induce robust immune responses. Therefore, it uncovered the MW-dependent immunoenhancing effects and mechanism of polysaccharide nanoparticles, providing a platform for designing potential nanosized polysaccharide immunomodulators for mRNA vaccines.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Extracellular vesicles in disease · Immunotherapy and Immune Responses
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Sichuan Engineering Research Center for Biomimetic Synthesis of Natural Drugs, School of Life Science and Engineering, Southwest Jiaotong University, Chengdu 610031, China
Funding
Southwest Jiaotong University · Fundamental Research Funds for the Central Universities · National Natural Science Foundation of China
References (47)
Show source-provided references
1. 10.1021/acs.accounts.1c0049310.1021/acs.accounts.1c00493 ↗
2. 10.1186/s12943-021-01311-z10.1186/s12943-021-01311-z ↗
3. 10.1038/nrd.2017.24310.1038/nrd.2017.243 ↗
4. 10.1016/j.jconrel.2021.03.04310.1016/j.jconrel.2021.03.043 ↗
5. 10.1016/j.jconrel.2017.09.04110.1016/j.jconrel.2017.09.041 ↗
6. 10.1016/j.molmed.2017.01.00610.1016/j.molmed.2017.01.006 ↗
7. 10.1016/j.cell.2020.07.02410.1016/j.cell.2020.07.024 ↗
8. 10.1038/nbt.333010.1038/nbt.3330 ↗
9. 10.1016/j.vaccine.2018.07.04010.1016/j.vaccine.2018.07.040 ↗
10. 10.1016/j.biomaterials.2018.08.05410.1016/j.biomaterials.2018.08.054 ↗
11. 10.1016/j.immuni.2016.02.00410.1016/j.immuni.2016.02.004 ↗
12. 10.1016/j.biomaterials.2017.03.02210.1016/j.biomaterials.2017.03.022 ↗
13. 10.3390/ijerph18231263610.3390/ijerph182312636 ↗
14. McCarthy R. · Immunology · 1977 · 32 · 963
15. 10.1021/acsnano.8b0766210.1021/acsnano.8b07662 ↗
16. 10.1002/adma.20150539510.1002/adma.201505395 ↗
17. 10.1021/nn305700510.1021/nn3057005 ↗
18. 10.1126/sciadv.aaz446210.1126/sciadv.aaz4462 ↗
19. 10.1016/j.ijbiomac.2021.12.12910.1016/j.ijbiomac.2021.12.129 ↗
20. 10.1021/acs.nanolett.9b0348310.1021/acs.nanolett.9b03483 ↗
21. 10.3390/pharmaceutics1112068010.3390/pharmaceutics11120680 ↗
22. 10.1021/acs.accounts.1c0054410.1021/acs.accounts.1c00544 ↗
23. 10.1016/j.biomaterials.2020.12043110.1016/j.biomaterials.2020.120431 ↗
24. 10.1016/S0092-8674(88)91043-410.1016/S0092-8674(88)91043-4 ↗
25. 10.1111/j.0105-2896.2005.00301.x10.1111/j.0105-2896.2005.00301.x ↗
26. 10.1038/s41418-018-0251-z10.1038/s41418-018-0251-z ↗
27. 10.1158/2326-6066.CIR-15-023510.1158/2326-6066.CIR-15-0235 ↗
28. 10.4049/jimmunol.130169510.4049/jimmunol.1301695 ↗
29. 10.1016/j.intimp.2021.10752910.1016/j.intimp.2021.107529 ↗
30. 10.1007/s13105-022-00871-y10.1007/s13105-022-00871-y ↗
31. 10.3389/fimmu.2020.0046010.3389/fimmu.2020.00460 ↗
32. 10.1038/ni.327310.1038/ni.3273 ↗
33. 10.3389/fimmu.2021.67677310.3389/fimmu.2021.676773 ↗
34. 10.1016/j.biomaterials.2019.02.02610.1016/j.biomaterials.2019.02.026 ↗
35. 10.1074/jbc.M70282420010.1074/jbc.M702824200 ↗
36. 10.1002/art.3797710.1002/art.37977 ↗
37. 10.1002/jor.2269910.1002/jor.22699 ↗
38. 10.3389/fimmu.2020.59180310.3389/fimmu.2020.591803 ↗
39. 10.1016/j.jconrel.2021.12.02710.1016/j.jconrel.2021.12.027 ↗
40. 10.1002/bit.2764710.1002/bit.27647 ↗
41. 10.1016/j.immuni.2020.05.01310.1016/j.immuni.2020.05.013 ↗
42. 10.1016/j.cell.2017.09.03910.1016/j.cell.2017.09.039 ↗
43. 10.1038/s41586-019-1006-910.1038/s41586-019-1006-9 ↗
44. 10.1016/j.immuni.2021.01.01810.1016/j.immuni.2021.01.018 ↗
45. Zhong Z. · Clin. Exp. Rheumatol. · 2016 · 34 · 12
46. 10.1016/S0022-1759(98)00204-X10.1016/S0022-1759(98)00204-X ↗
47. 10.1016/j.jconrel.2016.02.03210.1016/j.jconrel.2016.02.032 ↗